Vladimir Akoyev, Ph.D., Vice President, Manufacturing Sciences
Mr. Akoyev leads the team responsible for analytical method development, validation, and support. His expertise includes a wide spectrum of biophysical and biochemical methods of protein characterization including mass spectrometry, HPLC, capillary electrophoresis, spectroscopy, scanning calorimetry, and ultracentrifugation. His team is also responsible for product stability programs and potency bioassay development. Before joining Ventria in 2010, Dr. Akoyev was a Senior Scientist at Kansas State University. Prior to this, he was a Research Scientist in the Institute of Cell Biophysics at the Russian Academy of Sciences, where he received his Ph.D. in Biophysics and Hematology.
Randall Alfano, Ph.D.,
Vice President, InVitria Product Development
Dr. Alfano joined Ventria in 2012 and currently leads the product development team, where he utilizes his expertise in media design and optimization for biomanufacturing and stem/primary cells. Prior to joining the Company, Dr. Alfano was the Process Development Manager for XBiotech in Austin, TX where he specialized in the development and optimization of the company’s cell culture processes in mammalian cells for cancer biologics. Previously, he was promoted from Postdoctoral Fellow to Senior Scientist at the Cancer Research Institute of Scott and White Hospital where he developed in vivo animal models for metastatic prostate cancer and was instrumental in developing thorough in vitro and in vivo models for immunostimulatory antigens. Dr. Alfano received his Ph.D. from Texas A&M Health Science Center College of Medicine.
Scott E. Deeter, President and CEO
Seymour Fein, M.D., Chief Medical Officer
Dr. Fein began his career at Hoffmann-La Roche Ltd. as a senior research physician and was responsible for a clinical development program that led to U.S. Food and Drug Administration (FDA) approval of recombinant interferon-alpha for cancer treatment. Dr. Fein was also the medical director of Bayer Healthcare Pharmaceuticals (U.S.) where he was responsible for therapeutic areas including gastroenterology, oncology, and cardiology. He later served as medical director for Rorer Group (now part of Sanofi) and Ohmeda (now part of Baxter). Dr. Fein founded and has been managing partner of a clinical and regulatory consulting organization and has worked closely with the Division of Gastroenterology and Inborn Errors Products at the FDA. He has participated in the development of and FDA approval of numerous drug products in many therapeutic areas. Dr. Fein has successfully overseen entrepreneurial drug development leading to the FDA approval of two orphan drug products in the field of gastroenterology.
Patrick Smith, Director, Quality
Pat Smith, Director of Quality, leads Ventria’s Quality Control and Quality Assurance teams. In this role, he has implemented cGMP protocols and maintains ISO 9001:2008 certification and quality systems for Ventria’s product line. Pat joined the company in 2010 after previously managing Quality, Supply Chain, and Facilities for ALK Abello, the largest allergy immunotherapy pharmaceutical company, at its US headquarters in Round Rock, TX. Prior to ALK Abello, he was Laboratory Director at Allergy Laboratories, Inc. He received his Bachelor of Science in Microbiology from The University of Oklahoma.